Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | 2 | 2 | — | — | — | 2 |
Drug common name | DELANZOMIB |
INN | delanzomib |
Description | Delanzomib is a C-terminal boronic acid peptide inhibitor which induces apoptosis in multiple myeloma, hematological and solid tumor cell lines. It has a role as a proteasome inhibitor, an apoptosis inducer and an antineoplastic agent. It is a threonine derivative, a phenylpyridine, a C-terminal boronic acid peptide and a secondary alcohol. It is functionally related to a L-threonine. |
Classification | Small molecule |
Drug class | proteozome inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(-c2ccccc2)n1)[C@@H](C)O)B(O)O |
PDB | — |
CAS-ID | 847499-27-8 |
RxCUI | — |
ChEMBL ID | CHEMBL270515 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB11956 |
UNII ID | 6IF28942WO (ChemIDplus, GSRS) |